BCR-ABL P210 (mbcr) One-Step Detection Kit

Cat Number: BCR210-QRT46

The BCR-ABL P190 (mbcr) One-Step Detection Kit is a real-time PCR-based assay designed to detect and quantify the BCR-ABL fusion transcript, a key biomarker associated with Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL), enabling precise molecular analysis of RNA samples.

Analytical sensitivity at 10^-4.5
One –step cDNA synthesis
46 tests per kit
Absolute and relative quantification options available
Aligned with the international scale
Low RNA input requirements
Less than 2-hour turnaround time
Complementary EntroGen PCR Analysis Software
Works with peripheral blood or bone marrow
Multiplexed detection of both target and internal control genes in the same well
Low positive control available to assist in assay validation and monitoring
For research use (RUO) in the U.S
For in vitro diagnostic use (IVD) in the European Union

Category: Leukemia Tag: BCR-ABL P210

Request More Information

Chromosomal translocations are among the most significant genetic alterations in leukemia and serve as key biomarkers for disease classification, prognosis, and research into targeted therapies. One of the most well-characterized translocations in leukemia involves the fusion of the BCR gene on chromosome 22 and the ABL gene on chromosome 9, forming the Philadelphia chromosome (Ph). This aberration is present in approximately 95% of chronic myeloid leukemia (CML) cases and about 35% of acute lymphoblastic leukemia (ALL) cases. The resulting fusion gene, BCR-ABL P210 (Mbcr), encodes a constitutively active tyrosine kinase that drives uncontrolled cell proliferation and leukemia progression.

This dual-target design enables accurate fusion gene quantification using the comparative Ct method (Pfaffl method), eliminating the need for external reference standards of known copy numbers.

The use of hot-start DNA polymerase, optimized primers, and hydrolysis probes ensures high specificity, reproducibility, and ultra-sensitive detection, capable of identifying as few as 2 copies of the fusion transcript per 5 µL of RNA input.

A low positive control for the BCR-ABL p210 One-Step Detection Kit is available and sold separately to support assay validation and performance monitoring.

By enabling highly sensitive and accurate detection of the BCR-ABL P210 (Mbcr) fusion transcript, this kit supports clinical research and molecular monitoring of Ph-positive CML and ALL, facilitating effective treatment management and early detection of molecular relapse.

The BCR-ABL P210 (mbcr) One-Step Detection Kit follows a simple and easy to use process. It can be completed in 2 hours.

EntroGenʼs BCR-ABL P210 (mbcr) One-Step Detection Kit requires a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes. This test includes reagents required for PCR amplification/detection, as well as validated reaction controls.

The BCR-ABL P210 (mbcr) One-Step Detection Kit features a streamlined workflow, incorporating first-strand cDNA synthesis and real-time PCR amplification in a single reaction well.

The kit does not include reagents or columns for RNA isolation.